<DOC>
	<DOC>NCT02852837</DOC>
	<brief_summary>The purpose of this study is to evaluate the tolerability, safety and the pharmacokinetic (PK) profile of daratumumab in Chinese participants with relapsed or refractory multiple myeloma (MM) who failed at least 2 prior lines of systemic therapy.</brief_summary>
	<brief_title>Dose Escalation Study of JNJ-54767414 (Daratumumab) in Chinese Participants With Relapsed or Refractory Multiple Myeloma Who Failed at Least 2 Prior Lines of Systemic Therapy</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms, Plasma Cell</mesh_term>
	<mesh_term>Daratumumab</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Documented multiple myeloma (MM) with measurable disease according to protocoldefined criteria Relapsed or refractory multiple myeloma after receiving at least 2 prior lines of therapy Eastern Cooperative Oncology Group performance status score of 0, 1, or 2 Adequate recovery from prior therapy Received daratumumab or other antiCD38 therapies previously Previously received an allogenic stem cell transplant or has received an autologous stem cell transplantation within 12 weeks Exhibiting clinical signs of meningeal involvement of multiple myeloma Known chronic obstructive pulmonary disease, known moderate or severe persistent asthma within the past 2 years, or uncontrolled asthma of any classification Known clinically significant cardiac disease Seropositive for human immunodeficiency virus, hepatitis B surface antigen positivity, or positive for antihepatitis C virus antibody Has plasma cell leukemia, Waldenstrom's macroglobulinemia, POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes), or amyloidosis Abnormal laboratory values according to protocoldefined parameters at screening</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>